title: Use of recombinant IL-2 (RU49637) after autologous bone marrow transplantation (BMT) in patients with hematological neoplasias: a phase 1 study.
authors.affiliation: BMT Unit, Institut Paoli Calmettes, Marseille, France.
authors.forename: D
authors.initials: D
authors.lastname: Blaise
authors.forename: A M
authors.initials: AM
authors.lastname: Stoppa
authors.forename: D
authors.initials: D
authors.lastname: Olive
authors.forename: M
authors.initials: M
authors.lastname: Brandely
authors.forename: P
authors.initials: P
authors.lastname: Tiberghien
authors.forename: M
authors.initials: M
authors.lastname: Attal
authors.forename: J
authors.initials: J
authors.lastname: Attal
authors.forename: J
authors.initials: J
authors.lastname: Reiffers
authors.forename: F
authors.initials: F
authors.lastname: Demeocq
authors.forename: J L
authors.initials: JL
authors.lastname: Pico
mesh_terms: D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D004341:Drug Evaluation; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007376:Interleukin-2 / Q000627:therapeutic use*; D007938:Leukemia / Q000276:immunology / Q000601:surgery / Q000628:therapy*; D008223:Lymphoma / Q000276:immunology / Q000601:surgery / Q000628:therapy*; D011994:Recombinant Proteins / Q000627:therapeutic use; D014182:Transplantation, Autologous
chemical_list: D007155:Immunologic Factors; D007376:Interleukin-2; D011994:Recombinant Proteins